是地高辛还是给患者开了地高辛？随机试验对于辨别地高辛与死亡率增加之间关联的主要风险因素至关重要。 - Suppr | 超能文献

Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality.

作者信息

Yildiz Ali, Soydinc Serdar

机构信息

Hacettepe University School of Medicine, Department of Cardiology, 06100 Ankara, Turkey.

Hacettepe University School of Medicine, Department of Cardiology, 06100 Ankara, Turkey.

出版信息

Int J Cardiol. 2015 Apr 1;184:512-513. doi: 10.1016/j.ijcard.2015.03.029. Epub 2015 Mar 3.

DOI:10.1016/j.ijcard.2015.03.029

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality.是地高辛还是给患者开了地高辛？随机试验对于辨别地高辛与死亡率增加之间关联的主要风险因素至关重要。

Int J Cardiol. 2015 Apr 1;184:512-513. doi: 10.1016/j.ijcard.2015.03.029. Epub 2015 Mar 3.

2

Response to "Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality".对《地高辛还是使用地高辛的患者？随机试验对于鉴别地高辛与死亡率增加之间关联的主要危险因素至关重要》的回应

Int J Cardiol. 2015 Jun 15;189:247-8. doi: 10.1016/j.ijcard.2015.04.125. Epub 2015 Apr 16.

3

Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation.在接受抗凝治疗的房颤患者中，地高辛治疗与全因死亡率和心血管死亡率增加相关。

Int J Cardiol. 2015 Feb 1;180:1-5. doi: 10.1016/j.ijcard.2014.11.112. Epub 2014 Nov 18.

4

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).地高辛在伴有不良心血管结局的心房颤动患者中的应用：利伐沙班每日一次口服直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞的临床试验（ROCKET AF）的回顾性分析。

Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6.

5

Impact of Digoxin on Mortality in Patients With Atrial Fibrillation Stratified by Heart Failure: Findings From Gulf Survey of Atrial Fibrillation Events in the Middle East.地高辛对心力衰竭分层的心房颤动患者死亡率的影响：中东地区心房颤动事件海湾调查结果

J Cardiovasc Pharmacol Ther. 2016 May;21(3):273-9. doi: 10.1177/1074248415603505. Epub 2015 Sep 3.

6

Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.地高辛治疗心房颤动和心房扑动：随机临床试验的系统评价与荟萃分析和试验序贯分析。

PLoS One. 2018 Mar 8;13(3):e0193924. doi: 10.1371/journal.pone.0193924. eCollection 2018.

7

Digoxin and mortality in atrial fibrillation: a prospective cohort study.地高辛与心房颤动患者死亡率：一项前瞻性队列研究。

Eur J Clin Pharmacol. 2007 Oct;63(10):959-71. doi: 10.1007/s00228-007-0346-9. Epub 2007 Aug 8.

8

Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure.在≥65 岁伴或不伴心力衰竭的心房颤动患者中，地高辛的使用与全因死亡率的关系。

Am J Cardiol. 2014 Aug 1;114(3):401-6. doi: 10.1016/j.amjcard.2014.05.013. Epub 2014 May 16.

9

Digoxin mortality in heart failure and atrial fibrillation.

Eur Heart J. 2015 Aug 7;36(30):1944-5.

10

Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not?用于心房颤动和心力衰竭患者的地高辛：失乐园与否？

Eur Heart J. 2013 May;34(20):1468-70. doi: 10.1093/eurheartj/ehs483. Epub 2013 Jan 16.

引用本文的文献

1

Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis.地高辛治疗与心房颤动患者全因死亡率增加相关：一项更新的荟萃分析。

Medicine (Baltimore). 2015 Dec;94(52):e2409. doi: 10.1097/MD.0000000000002409.